Hemostemix cheers 17 "years of line gained" by Lindeman

Executive Summary

• Hemostemix Inc. highlights a 17-year survival case of a patient treated with its VesCell (ACP-01) therapy for ischemic cardiomyopathy, coinciding with new Florida legislation authorizing the use of VesCell for life-threatening conditions.
• The company reports that VesCell has treated 498 patients across seven clinical studies, with published data showing up to a 47.1% increase in ejection fraction in dilated cardiomyopathy patients.
• A recent peer-reviewed article in Cells (June 29, 2025) provides scientific backing for the therapy's mechanism, including angiogenesis and inflammation reduction, while the company notes a 0% mortality rate in a specific chronic limb-threatening ischemia (CLTI) study.

Key Details

• Patient Case Study: Howie Lindeman, a 6-time Grammy-winning producer, received VesCell treatment in 2008 for ischemic cardiomyopathy.
  • Outcome: Gained 17+ years of life; ejection fraction nearly doubled from the low-20% range to the 40% range.
  • Symptoms: Reported improved strength, health, and hope compared to pre-treatment fatigue and limitations.
• Regulatory Update: Florida law now authorizes the use of VesCell for patients with life-threatening or debilitating conditions who have exhausted standard-of-care options.
• Clinical Data & Statistics:
  • Total Patients Treated: 498 patients across seven clinical studies.
  • Publications: Results published in 11 peer-reviewed publications.
  • Ejection Fraction Improvement: Up to a 47.1% increase in ejection fraction in dilated cardiomyopathy patients in peer-reviewed studies.
  • CLTI Study Results: In a phase II trial for chronic limb-threatening ischemia (CLTI), a midpoint result from the University of British Columbia and University of Toronto reported:
    • 0% mortality (compared to a 50% five-year mortality rate in the general CLTI population).
    • Cessation of pain.
    • Wound healing in 83% of patients followed for up to 4.5 years.
• Scientific Mechanism: A June 29, 2025, article in Cells details how VesCell (ACP-01) and NCP-01 foster angiogenesis, reduce inflammation, and enhance synaptic plasticity.

Notable Quotes

• Howie Lindeman (Patient): "This therapy gave me my life back... I feel stronger, healthier and more hopeful than I ever thought possible."
• Thomas Smeenk (CEO): "Stories like Howie's are our drum beat. They inspire us to make VesCell widely available to patients who have no other options."